Ibrutinib for Autoimmune Hemolytic Anemia in CLL Patients

We are studying whether ibrutinib can effectively treat autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia or similar conditions. The trial will also look at the safety and quality of life during treatment.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ibrutinib
Ibrutinib is a substance that targets immune cell signaling to treat certain blood cancers, such as chronic lymphocytic leukemia and mantle cell lymphoma.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
DIPARTIMENTO DI ONCOLOGIA CLINICA
Brescia, Italy
ARNAS G. Brotzu
SC EMATOLOGIA E CTMO
Cagliari, Italy
Azienda Ospedaliera Santa Croce E Carle
SC EMATOLOGIA
Cuneo, Italy

Sponsor: Fondazione Gimema Franco Mandelli Onlus
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.